CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open account
☰
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open account
✖

Fall in profits hurts Pfizer shares

Article By: ,  Financial Analyst
May 6, 2014 12:15 PM

The share price of pharmaceutical company Pfizer fell yesterday (May 5th) after it was revealed by the firm that it has recorded a sharp fall in its profits.

Stocks slipped in the US yesterday on the back of the announcement that profits for the first three months of the year were 15 per cent down on the figures for the same period in 2013.

Falling revenue was also revealed by the drugmaker in its latest financial results, which the firm explained was because various patents protecting the exclusivity of its products have expired.

Frank D'Amelio, Pfizer's chief financial officer, said in a statement that the financial performance of the company in the three-month period reflected the "continuing impact of product losses of exclusivity, the expiration and near-term termination of certain collaborations". He added that Pfizer's operating environment "remains challenging".

Pfizer has been making headlines in the last few weeks as news recently broke of a massive takeover bid for rival company AstraZeneca, which prompted leader of the Labour Party Ed Miliband to suggest a review should be ordered to look into competition in the pharmaceutical sector. Pfizer had launched a £63 billion offer for the UK firm in a merger offer that would create one of the largest companies on the planet if it was to go ahead.

Reasons for bid

Chairman and chief executive at Pfizer Ian Read said the firm believes there is "a highly compelling strategic, business and financial rationale for combining our businesses, with significant benefits for shareholders and stakeholders of both companies."

News of the takeover bid led to a sharp increase in the value of AstraZeneca last week, but Pfizer's fortunes appear to be going the other way, especially after the firm revealed revenues fell nine per cent – a drop of more than a billion dollars – in the first quarter to $11.35 billion.

Yesterday, the share price of Pfizer fell by 2.57 per cent on the New York Stock Exchange, although stocks in the firm did recover by 0.2 per cent in after-hours trading in the US.

Find up to date information on the FTSE 100 and spread betting strategies at City Index

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. CFD and Forex Trading are leveraged products and your capital is at risk. They may not be suitable for everyone. Please ensure you fully understand the risks involved by reading our full risk warning.

City Index is a trading name of StoneX Financial Ltd. Head and Registered Office: 1st Floor, Moor House, 120 London Wall, London, EC2Y 5ET. StoneX Financial Ltd is a company registered in England and Wales, number: 05616586. Authorised and regulated by the Financial Conduct Authority. FCA Register Number: 446717.

City Index is a trademark of StoneX Financial Ltd.

The information on this website is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement.

© City Index 2024